阿特珠单抗诱发的线性免疫球蛋白A大疱性皮肤病

Linear immunoglobulin A bullous dermatosis induced by atezolizumab.

作者信息

Almutairi Seba, Alessa Dana

机构信息

Division of Dermatology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh.

College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

出版信息

Dermatol Reports. 2024 Feb 8;16(3):9923. doi: 10.4081/dr.2024.9923. eCollection 2024 Sep 2.

DOI:10.4081/dr.2024.9923

PMID:39290558

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11404540/

Abstract

Linear immunoglobulin A bullous dermatosis (LABD) is a rare immune-mediated vesiculobullous disease that is reported to be induced by infections or medications. Atezolizumab is a monoclonal antibody that targets programmed cell death ligand-1 and has been used to treat multiple cancers. Here, we report a case of drug induced LABD following the administration of Atezolizumab.

摘要

线状免疫球蛋白A大疱性皮肤病（LABD）是一种罕见的免疫介导性水疱大疱性疾病，据报道可由感染或药物诱发。阿替利珠单抗是一种靶向程序性细胞死亡配体1的单克隆抗体，已被用于治疗多种癌症。在此，我们报告1例使用阿替利珠单抗后发生药物性LABD的病例。